Intelligence · Clinical Development
Pipeline search results
Programs matching “prostate-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 133 pipeline programs matching "prostate-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Docetaxel
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
ES414
Aptevo Therapeutics
Prostate Cancer
1 trial -
Enzalutamide
CORCEPT THERAPEUTICS INC
Prostate Cancer
1 trial -
Ipilimumab
Regeneron UK Limited
Stage III Prostate Cancer
1 trial -
JANX007
Janux Therapeutics
Prostate Cancer
1 trial -
JANX014
Janux Therapeutics
Prostate Cancer
1 trial -
JSB462
Novartis Pharmaceuticals
Metastatic Prostate Cancer (mCRPC)
1 trial -
NKTR-214 (Cohort A)
INOVIO PHARMACEUTICALS, INC.
Metastatic Castration-resistant Prostate Cancer
1 trial -
ORIC-944
Topiloric/Uriadec
Metastatic Prostate Cancer
1 trial -
PAN-301-1
Sensei Biotherapeutics
Prostate Cancer
1 trial -
PSA/IL-2/GM-CSF
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
REGN5678
Regeneron UK Limited
Prostate Cancer
1 trial -
Tarlatamab
Amgen
Neuroendocrine Prostate Cancer
1 trial -
Triprorelin for injection
The First People's Hospital of Lianyungang
Prostate Cancer (CRPC)
1 trial -
VIR-5500
Vir Biotechnology
Hormone-refractory Prostate Cancer
1 trial -
[225Ac]Ac-AKY-2519 (therapeutic)
Aktis Oncology
Castration Resistant Metastatic Prostate Cancer
1 trial -
engineered autologous T cells
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
illuccix 68Ga-PSMA-11 Total Body PET-CT
Telix Innovations
Metastatic Castration-resistant Prostate Cancer
1 trial -
pTVG-HP with rhGM-CSF
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
Academic Detailing
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
2025XJSLL-10
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Prostate Cancer (Diagnosis)
1 trial -
Accurate Prediction Artificial Intelligence Models
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Combination of targeted biopsy and systematic biopsy
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Combination of targeted biopsy and systematic biopsy
Peking University Third Hospital
Prostate Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.